Panacea Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.40 M
as on 26-06-2024
- Paid Up Capital ₹ 1.98 M
as on 26-06-2024
- Company Age 43 Year, 7 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 0.74 M
as on 26-06-2024
- Revenue 13.40%
(FY 2020)
- Profit -71.68%
(FY 2020)
- Ebitda -15.28%
(FY 2020)
- Net Worth 1.49%
(FY 2020)
- Total Assets 9.70%
(FY 2020)
About Panacea Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 2.40 M and a paid-up capital of Rs 1.98 M.
The company currently has active open charges totaling ₹0.74 M.
Balbir Bhinder, Varunjeet Bhinder, and Harbhajansingh Bhinder serve as directors at the Company.
- CIN/LLPIN
U24230MH1981PTC024347
- Company No.
024347
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 May 1981
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Panacea Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Varunjeet Bhinder  | Director | 16-Jan-2013 | Current |
| Balbir Bhinder | Director | 16-Aug-2012 | Current |
| Harbhajansingh Bhinder | Director | 16-Aug-2012 | Current |
Financial Performance of Panacea Pharma.
Panacea Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.4% increase. The company also saw a substantial fall in profitability, with a 71.68% decrease in profit. The company's net worth moved up by a moderate rise of 1.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Panacea Pharma?
In 2020, Panacea Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Himech Equipments Private LimitedActive 20 years 6 monthsVarunjeet Bhinder and Harbhajansingh Bhinder are mutual person
- Himech Energy Serives Private LimitedActive 4 months 9 days
Harbhajansingh Bhinder is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 20 Mar 1984 | ₹0.02 M | Open |
Indian Bank Creation Date: 08 Aug 1983 | ₹0.02 M | Open |
The Abhinav Co- Op. Bank Ltd. Creation Date: 27 Nov 1982 | ₹0.70 M | Open |
How Many Employees Work at Panacea Pharma?
Unlock and access historical data on people associated with Panacea Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Panacea Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Panacea Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
